ライフサイエンスコーパス: topoisomerase IV

1 the target proteins, GyrA (gyrase) and ParC (topoisomerase IV).

2 specifically target bacterial DNA gyrase and topoisomerase IV.

3 cted a fusion protein of the two subunits of topoisomerase IV.

4 hose formed with either the wild type Gyr or topoisomerase IV.

5 t does not require the catalytic activity of topoisomerase IV.

6 formed with Gyr (A59), the wild type Gyr, or topoisomerase IV.

7 difference in the drug interaction domain on topoisomerase IV.

8 ates of DNA religation mediated by S. aureus topoisomerase IV.

9 pping in parC, one of the two genes encoding topoisomerase IV.

10 indicating that the proteins are subunits of topoisomerase IV.

11 e ATP binding pockets of both DNA gyrase and topoisomerase IV.

12 e DNA helicase might overcome DNA gyrase and topoisomerase IV.

13 leaved complex for N. gonorrhoeae gyrase and topoisomerase IV.

14 to unlink precatenated sister chromosomes by Topoisomerase IV.

15 bind to the catalytic site of DNA gyrase and topoisomerase IV.

16 acidic residue in the A subunit of gyrase or topoisomerase IV.

17 eta (TOP2B), and two in bacteria, gyrase and topoisomerase IV.

18 he DNA cleavage reaction of Escherichia coli topoisomerase IV.

19 karyotic topoisomerases I and II, and E.coli topoisomerase IV.

20 1215 allele, encoding one of the subunits of topoisomerase IV.

21 Surprisingly, we find that the CTD of the topoisomerase IV A subunit, which shares limited sequenc

22 Topoisomerase IV, a prokaryotic type II topoisomerase, c

23 Protection of topoisomerase IV, a secondary target of quinolone action

24 In Escherichia coli, topoisomerase IV, a type II topoisomerase, mediates the

25 In bacteria, DNA gyrase and topoisomerase IV act ahead of the fork to keep DNA under

26 We demonstrated that DNA topoisomerase IV, acting in concert with topoisomerase I

27 In addition, the majority of topoisomerase IV activity in synchronized cell populatio

28 These observations suggest that topoisomerase IV activity in vivo might be dependent on

29 intermediates of DNA replication, even when topoisomerase IV activity is removed.

30 When topoisomerase IV activity was blocked, either with a dru

31 Following inhibition of gyrase, topoisomerase IV alone relaxed plasmid DNA to a final su

32 Topoisomerase IV also was able to distinguish DNA geomet

33 They are inhibitors of bacterial gyrase and topoisomerase IV and demonstrate clinically useful antib

34 e nonsupercoiling class, including bacterial topoisomerase IV and eukaryotic topoisomerase II enzymes

35 The hybrids inhibited the FQ targets, topoisomerase IV and gyrase, with potencies similar to n

36 with all the subunits of both DNA gyrase and topoisomerase IV and has measurable effects on their act

37 was attributable to an increased demand for topoisomerase IV and is unlikely to define a new role fo

38 ng sites located on bacterial DNA gyrase and topoisomerase IV and not utilized by marketed antibiotic

39 h exhibited micromolar inhibition of E. coli topoisomerase IV and of Staphylococcus aureus homologues

40 s between clinically relevant quinolones and topoisomerase IV and provide a likely mechanism for the

41 oroquinolone inhibitor of DNA gyrase, and to topoisomerase IV and were almost completely resistant to

42 olates contained mutations in both parC (DNA topoisomerase IV) and gyrA (DNA gyrase), which were show

43 inhibitory activities against DNA gyrase and topoisomerase IV, and (c) no inhibitory activity against

44 it the type 2 topoisomerases, DNA gyrase and topoisomerase IV, and can cleave DNA at sites where thes

45 Although topoisomerase IV appears to be the primary cytotoxic tar

46 Bacterial DNA gyrase and topoisomerase IV are essential enzymes that control the

47 Bacterial DNA gyrase and topoisomerase IV are well-characterized clinically valid

48 erial type II topoisomerases (DNA gyrase and topoisomerase IV) are of interest for the development of

49 two-hybrid screen using the ParE subunit of topoisomerase IV as bait.

50 g the subunits of the chromosomal decatenase topoisomerase IV) at restrictive temperatures by high-co

51 relaxation of negatively supercoiled DNA by topoisomerase IV becomes distributive, whereas relaxatio

52 ion of gyrase ahead of replication forks and topoisomerase IV behind them causes fluoroquinolone-medi

53 E-ParC55)2 dimer of Streptococcus pneumoniae topoisomerase IV bound to two DNA molecules: a closed DN

54 onorrhoeae type II topoisomerases gyrase and topoisomerase IV by AZD0914 (AZD0914 will be henceforth

55 iments that analyzed individual steps of the topoisomerase IV catalytic cycle were undertaken to addr

56 d that specific interactions between dif and topoisomerase IV caused cleavage at that site.

57 Removal of both topoisomerase I and topoisomerase IV caused the DNA to become hyper-negative

58 ne action in bacteria and a new way to study topoisomerase IV-chromosome interactions.

59 Based on these findings, we propose that topoisomerase IV cleaves DNA using a two-metal-ion mecha

60 These findings suggest that the MukB-topoisomerase IV complex may provide a scaffold for DNA

61 in the gyrA and parC genes of the DNA gyrase/topoisomerase IV complex that occurred in the presence o

62 DNA gyrase and topoisomerase IV control bacterial DNA topology by break

63 Bacterial DNA gyrase and topoisomerase IV control the topological state of DNA du

64 erial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent activity against Gram-p

65 erial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent antibacterial activity

66 are potent inhibitors of both DNA gyrase and topoisomerase IV, displaying antibacterial activities ag

67 y is required for formation of a norfloxacin-topoisomerase IV-DNA ternary complex that can arrest the

68 caffold against the N-terminal domain of the topoisomerase IV E subunit from Escherichia coli (eParE)

69 ses, DNA gyrase encoded by gyrB and gyrA and topoisomerase IV encoded by parE and parC.

70 bacterial condensin, and ParC, a subunit of topoisomerase IV, enhanced relaxation of negatively supe

71 ncodes a protein that does not interact with topoisomerase IV exhibit severe nucleoid decompaction le

72 tive feedback control of topoisomerase I and topoisomerase IV expression, which is typical of other b

73 Second, the preference of topoisomerase IV for catalyzing DNA decatenation over re

74 tion of Staphylococcus aureus DNA gyrase and topoisomerase IV from both bacteria.

75 he most balanced inhibitor of DNA gyrase and topoisomerase IV from both E. coli and S. aureus.

76 ibition of the topoisomerases DNA gyrase and topoisomerase IV from both Gram-positive and a Gram-nega

77 st DNA gyrase from Staphylococcus aureus and topoisomerases IV from E. coli and S. aureus were determ

78 ed with negatively supercoiled) DNA, whereas topoisomerase IV generated similar levels with both subs

79 Although bacterial gyrase and topoisomerase IV have critical interactions with positiv

80 erial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential to become such drug

81 ics otherwise known to target DNA gyrase and topoisomerase IV in bacterial cells.

82 tions normally carried out by gyrase and DNA topoisomerase IV in other bacteria.

83 sistance mediated by decreased expression of topoisomerase IV in Staphylococcus aureus.

84 When fluoroquinolones bind to gyrase or topoisomerase IV in the presence of DNA, they alter prot

85 ng that the ParEC protein can substitute for topoisomerase IV in vivo.

86 Inhibition of topoisomerase IV in wild-type cells increased supercoili

87 analog 49c was found to be a dual DNA gyrase-topoisomerase IV inhibitor, with broad antibacterial act

88 sed molecules that are potent DNA gyrase and topoisomerase IV inhibitors and display excellent antiba

89 ased optimization toward dual DNA gyrase and topoisomerase IV inhibitors with antibacterial activity.

90 ompounds toward balanced dual DNA gyrase and topoisomerase IV inhibitors with antibacterial activity.

91 s of bacterial topoisomerase (DNA gyrase and topoisomerase IV) inhibitors binding in the ATP domain a

92 in MukB and the cellular decatenating enzyme topoisomerase IV interact.

93 We show here that the MukB-topoisomerase IV interaction stabilizes MukB on DNA, inc

94 Topoisomerase IV is a bacterial type II topoisomerase th

95 that a fusion protein of the two subunits of topoisomerase IV is a functional topoisomerase.

96 Topoisomerase IV is the primary cellular target for most

97 Third, quinolones stimulate topoisomerase IV-mediated DNA cleavage both by increasin

98 rovafloxacin result from increased S. aureus topoisomerase IV-mediated DNA cleavage rather than inhib

99 Trovafloxacin induced topoisomerase IV-mediated DNA scission more rapidly than

100 that the particular substrate preferences of topoisomerase IV might be dictated in part by the functi

101 f topoisomerase III in temperature sensitive topoisomerase IV mutants in Escherichia coli results in

102 Dose-response experiments with two topoisomerase IV mutants that confer clinical resistance

103 When the test strain contained a preexisting topoisomerase IV mutation, which by itself conferred no

104 In these cells, ParC, one subunit of topoisomerase IV, no longer associated with the replicat

105 We conclude that topoisomerase IV, not gyrase, unknots DNA and that it is

106 ibacterial agents that attack DNA gyrase and topoisomerase IV on chromosomal DNA.

107 Using strains in which either DNA gyrase or topoisomerase IV, or both, were resistant to norfloxacin

108 FtsK is required for the localization of the topoisomerase IV ParC subunit to the replisome to facili

109 and the active domains of the E-subunits of topoisomerase IV (ParE) from a G(+) strain (Streptococcu

110 al inhibition of bacterial gyrase (GyrB) and topoisomerase IV (ParE), and it demonstrates efficacy in

111 es inhibit the overall catalytic activity of topoisomerase IV primarily by interfering with enzyme-AT

112 ally inactive and quinolone-resistant mutant topoisomerase IV proteins, nitrocellulose filter DNA bin

113 exes formed with either the wild type Gyr or topoisomerase IV remain stably bound.

114 iral arrangement of the DNA was required for topoisomerase IV stimulation because relaxation of posit

115 showed that selected compounds inhibited DNA topoisomerase IV, suggesting complex mechanisms of actio

116 equired the presence of either DNA gyrase or topoisomerase IV, suggesting that modulation of the topo

117 ulates intramolecular reactions catalyzed by topoisomerase IV, supercoiled DNA relaxation, and DNA kn

118 rmation for further developing drugs against topoisomerase IV targets.

119 r weight, synthetic inhibitors of gyrase and topoisomerase IV that bind to the ATP sites are presente

120 regions of ParE, one of the two subunits of topoisomerase IV, that are involved in catalysis during

121 ated locus TcaR, DNA-binding protein II, and topoisomerase IV, that bound to the ica promoter.

122 As is the case with topoisomerase IV, the active cleavage and reunion activi

123 S81F/E85A) and GrlA(S81F) Bacillus anthracis topoisomerase IV, their sensitivity to quinolones and re

124 groups when reconstituted with ParC to form topoisomerase IV, those that elicited hyper-DNA cleavage

125 us anthracis and Escherichia coli gyrase and topoisomerase IV to relax and cleave positively supercoi

126 to evaluate contributions of gyrase and DNA topoisomerase IV to resistance.

127 s indicate that gyrase is better suited than topoisomerase IV to safely remove positive supercoils th

128 n topoisomerase IIalpha and Escherichia coli topoisomerase IV, to distinguish supercoil geometry duri

129 nventional type II topoisomerases, including topoisomerase IV, to DNA takes place at the catalytic do

130 timicrobial drugs target both DNA gyrase and topoisomerase IV (Topo IV) and convert these essential e

131 erial drugs target both DNA gyrase (Gyr) and topoisomerase IV (Topo IV) and form topoisomerase-quinol

132 n Escherichia coli, the MukB/E/F complex and topoisomerase IV (Topo IV) are both crucial players in t

133 DNA gyrase and topoisomerase IV (Topo IV) are cellular targets of quino

134 DNA gyrase and topoisomerase IV (Topo IV) are type II bacterial DNA top

135 We have studied the stimulation of topoisomerase IV (Topo IV) by the C-terminal AAA+ domain

136 DNA gyrase and topoisomerase IV (Topo IV) have distinct roles as unlink

137 ntified the parC and parE genes encoding DNA topoisomerase IV (Topo IV) in Caulobacter crescentus.

138 Topoisomerase IV (Topo IV) is a mediator of quinolone to

139 Escherichia coli topoisomerase IV (topo IV) is an essential enzyme that u

140 We showed recently that topoisomerase IV (topo IV) is the only important decaten

141 We found that both DNA gyrase and topoisomerase IV (topo IV) promote replication fork prog

142 DNA collision frequency for Escherichia coli topoisomerase IV (topo IV) that displays efficient non-e

143 ke component of the bacterial condensin, and topoisomerase IV (Topo IV), a type II topoisomerase that

144 In Escherichia coli, topoisomerase IV (Topo IV), encoded by parE and parC, is

145 ial type IIA topoisomerase, Escherichia coli topoisomerase IV (topo IV), using a combination of site-

146 of parE, encoding the ATP-binding subunit of topoisomerase IV (Topo IV), were purified and their acti

147 We have previously shown that DNA topoisomerase IV (topo IV), which is encoded by the parE

148 ParE and ParC proteins reconstituted to form topoisomerase IV (topo IV), which was highly proficient

149 t assay was employed to assess the effect of topoisomerase IV (Topo IV)-norfloxacin-DNA ternary compl

150 stigated the effects of abasic (AP) sites on topoisomerase IV (Topo IV).

151 the preferred substrate for Escherichia coli topoisomerase IV (topo IV).

152 ParE is the ATP-binding subunit of topoisomerase IV (Topo IV).

153 fore they undergo a complete decatenation by topoisomerase IV (Topo IV).

154 oils, a feature shared with Escherichia coli topoisomerase IV (Topo IV).

155 on was 50-60 bp for DNA gyrase and 40 bp for topoisomerase IV (Topo IV).

156 n with ori, and limiting the availability of topoisomerase IV (TopoIV) at ter.

157 Finally, topoisomerase IV unknotted DNA equally well when DNA rep

158 ch is strongly affected by DNA supercoiling, topoisomerase IV unknotted DNA independently of supercoi

159 The role of topoisomerase IV was revealed by two functional assays.

160 e distribution of ParE, the other subunit of topoisomerase IV, was unaffected.

161 religation reaction of Staphylococcus aureus topoisomerase IV were characterized.

162 eligation reactions of Staphylococcus aureus topoisomerase IV were characterized.

163 ted directly that both topoisomerase III and topoisomerase IV were efficient at this task, whereas DN

164 f negatively supercoiled DNA and knotting by topoisomerase IV, which are intramolecular DNA rearrange

165 activities against S. aureus DNA gyrase and topoisomerase IV, with weak activity against human topoi

166 positive supercoiling behind the fork where topoisomerase IV would also act to maintain replicating

167 We found that Escherichia coli topoisomerase IV, yeast topoisomerase II and human topoi